Time limits apply in Pennsylvania. Find out if you still qualify.
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Verified against court and regulatory records · No upfront fees · Your information is never sold
Statute of limitations — Pennsylvania
Pennsylvania Consolidated Statutes 42 Pa. C.S. § 5524 imposes a 2-year statute of limitations for personal injury claims including product liability. The discovery rule applies where the defect or its causal connection was not immediately discoverable — the clock starts when the plaintiff knew or should have known that Elmiron caused the vision damage. Pennsylvania does not have a statute of repose for pharmaceutical product liability claims.
2 years from discovery of Elmiron-related vision injury
Filing venue
Where to File in Pennsylvania
Federal Elmiron cases from Pennsylvania are transferred to the MDL in the District of New Jersey (MDL No. 2973). Pennsylvania state court claims may proceed in Philadelphia County Court of Common Pleas, which has a dedicated mass tort program and has historically been among the most plaintiff-favorable pharmaceutical litigation venues in the nation. Pennsylvania applies a Frye standard for expert testimony in state courts. Pennsylvania's proximity to the D.N.J. MDL court and strong pharmaceutical litigation tradition make it a significant source of Elmiron claims.
Pennsylvania data
Exposure in Pennsylvania
Pennsylvania population — fifth-largest state with major urology treatment centers at Penn Medicine, Thomas Jefferson, and UPMC
13 million
Source: U.S. Census Bureau 2024
Pennsylvania does not impose a statute of repose for pharmaceutical product liability — critical for Elmiron patients who used the drug for decades before the retinal risk was identified
No repose
Source: Pa. product liability law
Prevalence of macular changes found in Elmiron users regardless of exposure duration in a Kaiser Permanente retrospective study, rising significantly with longer use
11%
Source: Kaiser Permanente / Ophthalmology (2019)
Keep reading